This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (31)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Its Therapeutic Effect in Patients With Disease Poorly Controlled by Insulin Alone

Claude K. Lardinois, MD; George C. Liu, MD, PhD; Gerald M. Reaven, MD

Arch Intern Med. 1985;145(6):1028-1032.

Abstract
• Glyburide, a second-generation sulfonylurea compound, was combined with insulin to evaluate its therapeutic effectiveness in 14 patients with non-insulin-dependent diabetes mellitus (NIDDM), poorly controlled by insulin alone. Patients were studied before and three months after the addition of glyburide to their insulin program. Fasting plasma glucose concentration fell an average of 57 mg/dL, associated with an approximately 25% reduction in postprandial glucose response. Therapeutic responses varied widely from patient to patient; the greatest improvement in diabetic control was seen in heavier patients, who had retained the ability to secrete insulin in response to meals and who were not excessively insulin resistant. The glyburide-induced fall in plasma glucose concentration was associated with improvements in both insulin secretion and insulin action, but only the enhanced insulin action correlated with the reduction in fasting and postprandial glucose levels. Thus, diabetic control was significantly improved by glyburide. Combined insulin-sulfonylurea therapy may be useful in the treatment of NIDDM that cannot be easily controlled with either agent alone.

(Arch Intern Med 1985;145:1028-1032)

Author Affiliations
From the Department of Medicine, Stanford (Calif) University School of Medicine, and the Geriatric Research, Education and Clinical Center, Veterans Administration Medical Center, Palo Alto, Calif.

Footnotes
Accepted for publication Oct 23, 1984.

Reprint requests to VA Medical Center (640/182B), 3801 Miranda Ave, Palo Alto, CA 94304 (Dr Reaven).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy of Insulin and Sulfonylurea Combination Therapy in Type II Diabetes: A Meta-analysis of the Randomized Placebo-Controlled Trials
Johnson et al.
Arch Intern Med 1996;156:259-264.
ABSTRACT  

Insulin plus a Sulfonylurea Agent for Treating Type 2 Diabetes
Peters and Davidson
ANN INTERN MED 1991;115:45-53.
ABSTRACT  

Addition of Sulfonylurea to Insulin Treatment in Poorly Controlled Type II Diabetes: A Double-blind, Randomized Clinical Trial
Schade et al.
JAMA 1987;257:2441-2445.
ABSTRACT  

Insulin and a Sulfonylurea Agent in Non-Insulin-Dependent Diabetes Mellitus
Longnecker et al.
Arch Intern Med 1986;146:673-676.
ABSTRACT